Pure Global

Liquid Biospy for Urinary Cancers - Trial NCT06116396

Access comprehensive clinical trial information for NCT06116396 through Pure Global AI's free database. This phase not specified trial is sponsored by IRCCS San Raffaele and is currently Recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 450 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06116396
Recruiting
genetic
Trial Details
ClinicalTrials.gov • NCT06116396
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Liquid Biospy for Urinary Cancers
Use of Urinary Tumor Cells and Circulating Tumor Cells (CTCs) in the Prognosis and Therapy of Patients With Bladder (BCa) and Upper Urinary Tract (UTUC) Cancer

Study Focus

Urothelial Carcinoma

Genetic analysis on isolated cells

Observational

genetic

Sponsor & Location

IRCCS San Raffaele

Milan, Italy

Timeline & Enrollment

N/A

Sep 29, 2020

Sep 29, 2028

450 participants

Primary Outcome

Prognostic role of the liquid biopsy

Summary

The project aims to characterize the prognostic role of CTCs in Bladder cancer patients, with
 the specific aims to better stratify patients with non-muscle invasive bladder cancer at the
 first transurethral resection of tumor and to identify urothelial biomarker expressed by
 CTCs.

ICD-10 Classifications

Carcinoma in situ: Other and unspecified urinary organs
Malignant neoplasm of ureter
Malignant neoplasms of urinary tract
Malignant neoplasm: Overlapping lesion of urinary organs
Malignant neoplasm: Urethra

Data Source

ClinicalTrials.gov

NCT06116396

Non-Device Trial